InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intellige ... nce and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. read more